Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2013

View Archived Issues

Phase I data presented for RPC-1063 in IBD patients

Complementary biomarker for the diagnosis of gastrointestinal carcinoma described

Partnership to advance fusion protein for NHL

Results presented for Pulmagen's lead oral DP2 receptor antagonist ADC-3680

Blood thiamine metabolism as a non-invasive biomarker for AD diagnosis

HGT-1410 demonstrates rapid systemic distribution in vivo

New inhibitors of phosphate transport synthesized by Astellas

Merck & Co. patents novel GPR119 receptor agonists

Canadian group discloses new CBX2 modulators for cancer

Novel FABP inhibitors divulged by Roche

Merck & Co. presents novel bacterial vaccines

Companies announce termination of QVAR comarketing agreement

Rigel Pharmaceuticals set to advance to phase II trial for dry eye disease therapeutic

Scientists at Merck & Co. synthesize novel gamma-secretase modulators

HbA1c test receives marketing approval in U.S. for diabetes diagnosis

TauRx Therapeutics opens U.K. sites in phase III trials of LMTX

Bayer Yakuhin launches Stivarga tablets in Japan

Merck & Co. discontinues development of preladenant for Parkinson's disease

PharmaMar studies PM-01183 in combination with capecitabine

Nippon Shinyaku launches Regtect in Japan

Mitsubishi Tanabe Pharma seeks Japanese approval of canagliflozin

OncoTherapy Science obtains rights to results of collaborative research with Kumamoto University

Data show GCS-100 may improve renal function

Astellas submits marketing application in Japan for enzalutamide

Dosing begins in phase I trial of SB-9200 in HCV infection

Headline results reported from phase IIIa trial of liraglutide for obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...